VC  Tekla Capital Management

http://www.teklacap.com/





     Office Locations:

100 Federal Street, 19th Floor
Boston, MA 02110

 

Stages:

  • Growth


 

Industries:

  • Life Sciences & Healthcare

  •  

    Description:

    Founded in 1986, the Tekla Capital Management is an employee owned investment manager. Tekla is a registered investment advisor for four closed-end funds, Tekla Healthcare Investors, Tekla Life Sciences Investors, Tekla Healthcare Opportunities Fund and Tekla World Healthcare Fund. The Funds predominately invest in the securities of public and private healthcare companies. Tekla Healthcare Investors (HQH) is a non-diversified closed-end healthcare fund traded on the New York Stock Exchange under the ticker HQH. Tekla Life Sciences Investors (HQL) is a non-diversified closed-end healthcare fund traded on the New York Stock Exchange under the ticker HQL. Tekla Healthcare Opportunities Fund (THQ) is a non-diversified closed-end fund traded on the New York Stock Exchange under the ticker THQ. Tekla World Healthcare Fund (THW) is a non-diversified closed-end fund traded on the New York Stock Exchange under the ticker THW.



    Investment Firm Key

       VC = Venture Capital
       PE = Private Equity
       A = Angel
       I = Incubator
       MB = Merchant Bank
       VD = Venture Debt
       FI = Family Investment Office
       FOF = Fund of Funds
       ED = Economic Development Office   
       TT = Technology Transfer Office
       CVC = Corporate Venture Capital
       SEC = Secondary Purchaser
       HF = Hedge Fund/Mutual Fund
       
       
       
    COMPANY STAGEREVENUE
    Venture Capital
    Seed Stage
    (includes "pre-seed," or
    concept stage)
    No Revenue
    Early StageMinimal
    Revenue
    Growth Stage
    (also called Mid-stage)
    $2M-$7M
    Expansion Stage
    (also called Late-stage)
    $7M and greater
    Private Equity
    Lower Middle Market$10M-$249M
    Middle Market$250M-$499M
    Upper Middle Market$500M-$1B
    Large Cap>$1B
       
       
     

    Investment Team:


    Name   Title
    Get the complete investment team + individual email addresses for investment team partners. Get personal images, LinkedIn links, investment specialties, office locations and more with a National Database subscription.
    Chris Abbott Vice President, Research
    Daniel R. Omstead PhD President and CEO
    Jason C. Akus MBA, MD Senior Vice President, Research
    Laura Woodward CPA Chief Compliance Officer and Vice President of Fund Administration
    Robert Benson CFA, CAIA Senior Analyst, Research

     

    Recent Funding Events (trailing 12 months):


      Date


      Name


      State


      Amount


      Stage


      02/10/2022


      Arkuda Therapeutics


      MA


      $64,000,000


      Series B


     

    Portfolio companies include:

     

    Recent News: